全文获取类型
收费全文 | 3001篇 |
免费 | 176篇 |
国内免费 | 48篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 2篇 |
基础医学 | 10篇 |
口腔科学 | 2篇 |
临床医学 | 20篇 |
内科学 | 31篇 |
皮肤病学 | 5篇 |
神经病学 | 5篇 |
特种医学 | 32篇 |
外科学 | 21篇 |
综合类 | 435篇 |
预防医学 | 23篇 |
眼科学 | 3篇 |
药学 | 1872篇 |
中国医学 | 757篇 |
肿瘤学 | 5篇 |
出版年
2024年 | 42篇 |
2023年 | 106篇 |
2022年 | 135篇 |
2021年 | 200篇 |
2020年 | 165篇 |
2019年 | 250篇 |
2018年 | 218篇 |
2017年 | 200篇 |
2016年 | 162篇 |
2015年 | 85篇 |
2014年 | 183篇 |
2013年 | 137篇 |
2012年 | 201篇 |
2011年 | 180篇 |
2010年 | 130篇 |
2009年 | 93篇 |
2008年 | 100篇 |
2007年 | 116篇 |
2006年 | 125篇 |
2005年 | 60篇 |
2004年 | 76篇 |
2003年 | 61篇 |
2002年 | 40篇 |
2001年 | 45篇 |
2000年 | 28篇 |
1999年 | 20篇 |
1998年 | 9篇 |
1997年 | 14篇 |
1996年 | 14篇 |
1995年 | 7篇 |
1994年 | 7篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1986年 | 1篇 |
1985年 | 1篇 |
排序方式: 共有3225条查询结果,搜索用时 578 毫秒
41.
用薄层扫描法测定祛浊胶囊中熊果酸的含量。方法 以氯仿-醋酸乙酯-冰醋酸(5∶3∶0 .1)为展开剂,λS=5 30nm,λR=70 0nm。结果 平均回收率为97 .10 %,RSD =0 . 83%。结论 该方法简便,准确,可用于控制该产品的质量 相似文献
42.
43.
四神止泻胶囊的制备及其质量控制 总被引:1,自引:0,他引:1
目的:制备四神止泻胶囊,并建立质量控制方法。方法:采用薄层色谱法鉴别肉豆蔻、五味子和吴茱萸三味药材,高效液相色谱法测定成品中补骨脂素和异补骨脂素的含量。结果:肉豆蔻、五味子和吴茱萸薄层色谱斑点清晰;成品三批中补骨脂素和异补骨脂素含量稳定。结论:四神止泻胶囊制备工艺合理,质量控制方法可行。 相似文献
44.
目的:建立生化产复康胶囊中阿魏酸的含量测定方法。方法:采用高效液相色谱法,以kromasil C18柱为固定相,乙睛-0.085%磷酸溶液(17:83)为流动相,检测波长315nm,流速1.0ml/min,柱温35℃。结果:阿魏酸在0.076~0.228ug(r=0.9999)范围内线性关系良好,平均回收率为100.25%、RSD为1.84%。结论:本方法简便,准确,重现性好,可用于测定生化产复康胶囊中阿魏酸的含量。 相似文献
45.
46.
47.
48.
目的:建立复合氨基酸胶囊中5种水溶性维生素的含量测定方法.方法:采用高效液相色谱法,用乙腈与庚烷磺酸钠-磷酸钠的水溶液(pH=3.0)为流动相,流速1.0ml·min-1,色谱柱为C18(4.6×250mm,5μm),柱温40℃,检测波长为280nm,进样量为20μl.结果:维生素Bl、维生素B2、维生素B6、维生素C和烟酰胺分别在24.7~75.2μg·ml-1、15.0~44.9μg·ml-1、12.2~37.5μg·ml-1、99.2~299.9μg·ml-1和100.3~300.9μg·ml-1范围内呈线性关系,相关系数均为1.000,平均回收率均在100%±2%范围以内.RSD分别为0.19%、0.26%、0.46%、1.17%和0.52%.结论:本方法准确,简便,快捷,可以同时测定复合氨基酸胶囊中维生素B1、维生素B2、维生素B6、维生素C和烟酰胺的含量. 相似文献
49.
《Ultrasound in medicine & biology》2016,42(10):2391-2400
Our purpose was to evaluate the feasibility of using ultrasonographic criteria of thyroid capsular continuity and tumor contour to differentiate macroscopic extra-thyroidal extension (ETE) from microscopic ETE, as well as non-ETE from ETE. On ultrasonography, we evaluated thyroid capsular continuity (C0 = continuous, C1 = discontinuous, C2 = invisible), and thyroid tumor contour (P0 = in normal parenchyma, P1 = abutting, P2 = bulging), which were grouped into type 1–9 classifications. Either C1–2 or P1–2 was more prevalent in ETE than non-ETE. C1 and P2 tended to be associated with macroscopic ETE, whereas C0 and P1 were significantly associated with microscopic ETE. Types 6, 8 and 9 were more likely to have ETE than non-ETE; type 6 (C1 P2) and type 9 (C2 P2) were significantly associated with macroscopic ETE, whereas type 8 (C2 P1) was associated more with microscopic ETE. Macroscopic and microscopic ETE, as well as non-ETE and ETE, can be differentiated using these pre-operative ultrasonographic criteria. 相似文献
50.
Background:Although percutaneous coronary intervention(PCI)had become widely employed therapeutic procedure for coronary artery disease,stent restenosis limited the benefits of this revascularization and the question how to prevent such events remained unresolved.While numerous empirical observations suggested Tongguan Capsules(通冠胶囊),a patented Chinese Medicine,could decrease frequency and duration of angina pectoris attacks,evidence supporting its efficacy on restenosis remained inadequate.Objective:This trial was designed to determine whether Tongguan Capsules would reduce restenosis rate in patients after successful stent implantation.Methods:Approximately 400 patients undergoing percutaneous coronary stent deployment were enrolled and randomized to control group or Tongguan Capsules(4.5 g/d)for 3 months.All patients received standard anti-platelet,anti-coagulation and lipid-decreasing treatments,concurrently.The primary clinical endpoint was the 12-month incidence of the major adverse cardiovascular events(defined as cardiac death,myocardial infarction,and recurrence of symptoms requiring additional revascularization).The angiographic end point was restenosis rate at 6 months.Conclusion:This study would provide important evidence for the use of Tongguan Capsules in patients after stent implantation in combination with routine therapies,which may significantly reduce incidence of the restenosis so as to potentially improve the clinical outcomes.(registration number:ChiCTR-TRC-ChiCTR-IIR-17011407) 相似文献